<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20050915180114+02'00'</creation_date><modification_date>D:20060322183343+01'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-04-283_h_w_dec_2.pdf</pdf_file></head><body><section><header>en  
   en</header></section><section><header>en</header><p>commission of the european communities</p><p>brussels, 15-ix-2005 c(2005) 3579</p></section><section><header>commission decision of 15-ix-2005 
 amending, under article 18 of council regulation (eec) no 2309/93, the marketing 
 autorisation, granted by decision c(2004)3160, for &quot;ariclaim - duloxetine 
 hydrochloride&quot; a medicinal product for human use</header><p>only the german text is authentic</p></section><section><header>en  
   en</header></section><section><header>commission decision of 15-ix-2005 
 amending, under article 18 of council regulation (eec) no 2309/93, the marketing 
 autorisation, granted by decision c(2004)3160, for &quot;ariclaim - duloxetine 
 hydrochloride&quot; a medicinal product for human use 
 (text with eea relevance)</header><p>the commission of the european communities, having regard to the treaty establishing the european community,</p><p>
 having regard to council regulation (eec) no 2309/93 of 22 july 1993 laying down 
 community procedures for the authorisation and supervision of medicinal products for 
 human and veterinary use and establishing a european agency for the evaluation of 
 medicinal products
 1, and in particular article 10(2) thereof, having regard to the opinion of the european medicines agency, formulated by the 
 committee for medicinal products for human use on 23 june 2005, 
 having regard to commission regulation (ec) no 1085/2003 of 3 june 2003 concerning 
 the examination of variations to the terms of a marketing authorisation falling within the 
 scope of council regulation (eec) no 2309/93
 2, and in particular the third subparagraph of article 4 (5) and the first subparagraph of article 5 (7) thereof, 
 having regard to the notifications submitted by boehringer ingelheim international 
 gmbh under article 4(1) and article 5(1) of regulation (ec) no 1085/2003, 
 whereas: 
 (1)</p><p>the placing on the market of the medicinal product &quot;ariclaim - duloxetine 
 hydrochloride&quot;, which is entered in the community register of medicinal products 
 under the numbers eu/1/04/283/001-007 was authorised by commission 
 decision c(2004)3160 of 11 august 2004. 
 (2)</p><p>pursuant to article 18 (1) of regulation (eec) no 2309/93, the commission 
 requested the opinion of the committee on medicinal products for human use as 
 to whether, in the case of “ariclaim - duloxetine hydrochloride” one of the 
 measures referred to in title xi of directive 2001/83/ec of the european</p><p>
 1 oj l 214, 24.8.1993, p. 1 regulation as last amended by [regulation (ec) no 1647/2003 (oj l 245, 29.9.2003, p. 19)]. 
 2 oj l 159, 27.6.2003, p. 24.</p></section><section><header>en  
   en</header><p>parliament and of the council of 6 november 2001 on the community code relating to medicinal products for human use
 3 should be applied. (3)</p><p>the scientific assessment by the committee, the conclusions of which are set out 
 in the annex iv to this decision, has shown that a decision should be adopted 
 amending the marketing authorisation for the medicinal product concerned. 
 (4)</p><p>decision c(2004)3160 should therefore be amended accordingly. 
 (5)</p><p>between 28 april 2005 and 23 june 2005, the european medicines agency 
 acknowledged the validity of the type ia notification(s) and accepted the type ib 
 variation(s) submitted. it informed the marketing authorisation holder accordingly 
 and prepared a list of the notification(s). the variation(s) took effect from the date 
 of the communication of the acknowledgement of validity or acceptance by the 
 european medicines agency / within 30 days of the date of acknowledgement, by 
 the european medicines agency, of receipt of the valid notification(s). 
 (6)</p><p>the marketing authorisation should be updated, and decision c(2004)3160 
 amended accordingly. 
 (7)</p><p>the measures provided for in this decision are in accordance with the opinion of 
 the standing committee on medicinal products for human use, 
 (8)</p><p>for the sake of clarity and transparency, it is advisable, following the amendment 
 of part or parts of the annexes, to provide for a consolidated version thereof. the 
 annexes to decision c (2004)3160 should therefore be replaced, 
 has adopted this decision: 
 article 1 the marketing authorisation granted by decision c(2004)3160 of 11 august 2004 for the medicinal product “ariclaim - duloxetine hydrochloride” is amended, on the basis of the 
 scientific conclusions set out in the annex iv to this decision. 
 article 2 decision c(2004)3160 is amended as follows: 1) the list of notifications for minor variations submitted between 28 april 2005 and 23 
 june 2005 is added to the updated marketing authorisation. 
 application number 
 scope (eu numbers affected) 
 emea/h/c/552/ia/004 
 41.a.1 (ia) (eu/1/04/283/007)</p><p>
 3 oj l 311, 28.11.2001, p. 67. directive as last amended by [directive 2004/27/ec (oj l 136, 30.4.2004, p.34)].</p></section><section><header>en  
   en</header><p>emea/h/c/552/ib/005 42.a.1 (ib) (eu/1/04/283/001-007) 
 2) annex i is replaced by the text set out in annex i to this decision; 
 3) annex iii is replaced by the text set out in annex iii to this decision. 
 4) the following number is added to article 1 and entered in the community register of 
 medicinal products:</p><p>
 eu/1/04/283/007 
 ariclaim-20 mg-capsule, hard, gastro-resistant-oral use-blister 
 (pvc/pe/pctfe/alu)-28 capsules 
 article 3 this decision is addressed to boehringer ingelheim international gmbh, binger strasse 173, d-55216 ingelheim am rhein, deutschland. 
 done at brussels, 15-ix-2005 
 for the commission günter verheugen 
 member of the commission</p></section></body></xml>